Insider buying last 90 days
No open-market insider purchases were filed for MANE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MANE insider filing, plotted on the chart in Gekko.Open MANE in Gekko
NYSE: MANE
Veradermics (MANE) Stock Analysis & Forecast
Sep 28 close
$115.00−1.57 (−1.3%)
Gekko Brief
AI summaryVeradermics draws attention this week on a wave of analyst commentary, with brokerages assigning a consensus "Moderate Buy" rating and an average 12-month price target reported at $153.00. Shares were seen trading 6.1% higher to $119.64 on light volume during the period, and a separate piece points to expectations around how the company deploys its cash position. The tone across coverage remains positive, centered on analyst sentiment and cash usage rather than product or regulatory developments.
MANE closes at $115.00, down 1.3% on the day, sitting above its 50-day moving average of $106.76 and within its 52-week range of $32.00 to $131.24. The GekkoIndex reads 49.7, placing the stock in the Neutral zone, while the current price sits 4.1% below the Gekko Fair Value estimate of $119.91.
Looking ahead, the next earnings date falls on 10 November 2026, 42 days out and beyond a typical 20-trading-day holding window. Smart money data shows one billionaire holder and one trailblazer holder, though no insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Separately, analyst coverage from five firms carries a unanimous buy stance, with a consensus target of $163.50 implying 42.2% upside from current levels, a figure worth noting alongside the absence of near-term catalysts before the November report.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Veradermics price vs fair value
Close $115.00Gekko Fair Value $119.91
Veradermics quick facts
- Market cap
- $4.80B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$2.50
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- —
- Volume
- 633,454 avg 744,670
- 1-year return
- —
- Typical daily move
- ±5.2%
- Typical 20-day move
- ±15.7%
- 50-day average
- $106.76
- 200-day average
- —
- Next earnings
- Nov 10
- Shares outstanding
- 41.78M
Veradermics swing-trade checklist
Veradermics scores 1 supportive, 2 mixed and 0 headwinds across the 3 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive2 mixed0 headwinds
- Trendno data
No data
Not enough price history for both moving averages.
See the chart - GekkoIndexmixed
49.7, Neutral
Reading 49.7 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
4.1% below
Price is within 5% of Gekko Fair Value (4.1% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 42 days
Next report Nov 10, 2026, 42 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Veradermics stock chart and price history
Veradermics closed at $115.00 on Sep 28, 2026, inside a 52-week range of $32.00 to $131.24.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +13.0%
- 3 months
- −6.9%
- 6 months
- +75.5%
The full MANE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MANE in Gekko
Follow Veradermics through every session
Put MANE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MANE in GekkoFree for 7 days. No credit card required.
About Veradermics
Veradermics works on new drug candidates for skin and cosmetic conditions, with a pipeline built around treatments for pattern hair loss in both adults and children. Its best-known candidate is VDPHL01, a pill taken by mouth that does not rely on hormones and is meant for long-term management of hair loss in men and women with this condition. Alongside it, the company is developing VDMN, a dissolvable patch that uses immunotherapy to treat common warts, plus earlier programs aimed at alopecia areata, molluscum contagiosum, and atopic dermatitis.
Taken together, these programs are meant to serve dermatologists and aesthetic care providers who treat patients across age groups, as well as the broader dermatology research and clinical community.
Veradermics was founded in 2019 and is headquartered in New Haven, Connecticut. Its shares are listed on the NYSE under the ticker MANE.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- veradermics.com
Veradermics GekkoIndex: the smart money zone
Veradermics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 49.7, in the Neutral zone, up 0.3 points over five sessions.
49.7Neutral
Up 0.3 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 0 | Not available | |||
| Accumulation | 31 | +4.7% | +9.0% | ||
| Neutral (current zone) | 91 | +4.5% | +18.2% | ||
| Distribution | 20 | +0.4% | +0.1% | ||
| Selling | 0 | Not available | |||
Average MANE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the MANE price, zone by zone.Track MANE in Gekko
Is Veradermics stock overvalued? Gekko Fair Value
Veradermics trades 4.1% below Gekko Fair Value of $119.91, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Veradermics shares are worth, recalculated every trading day.
$119.91
Gekko Fair Value, Sep 26, 2026
4.1% below fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open MANE in Gekko
Veradermics insider and Congress trading
No open-market insider purchases were filed for Veradermics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in MANE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for MANE, plotted on the chart in Gekko.Open MANE in Gekko
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold MANE.
0added1opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Veradermics earnings: next date and track record
Veradermics reports on Nov 10, 2026 (42 days away), and beat the EPS estimate in 1 of its last 1 report.
Next earnings report
Nov 10, 2026
42 days away
- EPS estimate
- −$0.59
1 of 1reports beat the EPS estimate
±3.6%average move across the report
0 of 1reports followed by a gain
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 30, 2026 | −$0.76 est −$18.24 | — | −3.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Veradermics stock forecast and analyst price targets
Analysts’ average 12-month price target for Veradermics is $163.50, +42.2% from the last close, from 5 firms rating the stock in the last 90 days.
$163.50consensus 12-month target, +42.2% from the last close
Now $115.00Avg $163.50
Low $160High $182
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 15 | Citi | $160 | +39.1% |
| Sep 10 | Citi | $160 | +39.1% |
| Sep 8 | Jefferies | $182 | +58.3% |
| Aug 13 | Citi | $160 | +39.1% |
| Aug 12 | Needham | $164 | +42.6% |
+18.2%average 20-day move after past Neutral readings
±5.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Veradermics market cap and key statistics
Veradermics’s market cap is $4.80B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $4.80B
- EPS, TTM
- −$2.50
- Gekko Fair Value
- $119.91
Trading
- Volume
- 633,454
- Avg volume, 20 days
- 744,670
- 52-week high
- $131.24
- 52-week low
- $32.00
- Shares outstanding
- 41.78M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -72.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Typical daily move
- ±5.2%
- Typical 20-day move
- ±15.7%
Veradermics stock news this week
Coverage of Veradermics this week reads positive: 3 positive, 0 neutral and 0 negative headlines.
- Veradermics（NYSE: MANE）が現金を賢明に活用することを期待しています。Moomoo, Sep 26
- Veradermics (NYSE:MANE) Trading 6.1% Higher - What's Next?MarketBeat, Sep 22
- Veradermics, Incorporated (NYSE:MANE) Receives Consensus Rating of "Moderate Buy" from BrokeragesMarketBeat, Sep 21
- Veradermics, Incorporated (NYSE:MANE) Receives Consensus Rating of “Moderate Buy” from BrokeragesDefense World, Sep 21
Veradermics peers
Veradermics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Veradermics stock FAQ
What is Veradermics’s market cap?
Veradermics’s market cap is $4.80B at the Sep 28, 2026 close of $115.00, with 41.78M shares outstanding.
What is the Veradermics stock forecast?
The consensus analyst 12-month price target for Veradermics is $163.50, +42.2% from the last close. Of the 5 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Veradermics stock overvalued or undervalued?
On Gekko’s estimate Veradermics is about fair value: the Sep 28, 2026 close of $115.00 is 4.1% below Gekko Fair Value of $119.91. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Veradermics report earnings next?
Veradermics is expected to report on Nov 10, 2026 (42 days away). Analysts expect earnings of −$0.59 per share.
What is Veradermics’s 52-week high and low?
Veradermics’s 52-week high is $131.24 and its 52-week low is $32.00; it closed at $115.00 on Sep 28, 2026.
Is Veradermics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 3 items with data read as supportive (earnings risk), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Veradermics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.